| 1 | 
																						 
											 Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer [J]. N Engl J Med, 2016, 375(11): 1054-1067. 
																						 | 
										
																													
																							| 2 | 
																						 
											 Bikas A, Burman KD. Epidemiology of Thyroid Cancer [G]//Luster M, Duntas LH, Wartofsky L. Thyroid Its Dis. Cham: Springer International Publishing, 2019: 541-547. 
																						 | 
										
																													
																							| 3 | 
																						 
											 Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications [J]. Endoc. Rev, 2007, 28(7): 742-762. 
																						 | 
										
																													
																							| 4 | 
																						 
											 Niault TS, Baccarini M. Targets of Raf in tumorigenesis [J]. Carcinogenesis, 2010, 31(7): 1165-1174. 
																						 | 
										
																													
																							| 5 | 
																						 
											 Rashid FA, Munkhdelger J, Fukuoka J, et al. Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma—a contemporary systematic review [J]. Gland Surg, 2020, 9(5): 1878-1900. 
																						 | 
										
																													
																							| 6 | 
																						 
											 Kim TH, Park YJ, Lim JA, et al. The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis [J]. Cancer, 2012, 118(7): 1764-1773. 
																						 | 
										
																													
																							| 7 | 
																						 
											 Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis [J]. Medicine (Baltimore), 2012, 91(5): 274-286. 
																						 | 
										
																													
																							| 8 | 
																						 
											 Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J]. Thyroid, 2016, 26(1): 1-133. 
																						 | 
										
																													
																							| 9 | 
																						 
											 Wang W, Su X, He K, et al. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: an updated study with more than 2000 consecutive patients: bilateral vs unilateral-multifocal PTC [J]. Cancer, 2016, 122(2): 198-206. 
																						 | 
										
																													
																							| 10 | 
																						 
											 Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer [J]. JAMA, 2013, 309(14): 1493. 
																						 | 
										
																													
																							| 11 | 
																						 
											 Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer [J]. Nat Rev Endocrinol, 2011, 7(10): 569-580. 
																						 | 
										
																													
																							| 12 | 
																						 
											 Grogan RH, Mitmaker EJ, Clark OH. The evolution of biomarkers in thyroid cancer—from mass screening to a personalized biosignature [J]. Cancers, 2010, 2(2): 885-912. 
																						 | 
										
																													
																							| 13 | 
																						 
											 Rusinek D, Swierniak M, Chmielik E, et al. BRAFV600E-associated gene expression profile: early changes in the transcriptome, based on a transgenic mouse model of papillary thyroid carcinoma [J]. PLoS One, 2015, 10(12): e0143688. 
																						 | 
										
																													
																							| 14 | 
																						 
											 Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis [J]. Cancer, 2007, 110(1): 38-46. 
																						 | 
										
																													
																							| 15 | 
																						 
											 Ming J, Liu Z, Zeng W, et al. Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer [J]. Int J Clin Exp Pathol, 2015, 8(11): 15155-15162. 
																						 | 
										
																													
																							| 16 | 
																						 
											 Chakraborty A, Narkar A, Mukhopadhyaya R, et al. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion [J]. Endocr Pathol, 2012, 23(2): 83-93. 
																						 | 
										
																													
																							| 17 | 
																						 
											 Li C, Lee KC, Schneider EB, et al. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis [J]. J Clin Endocrinol Metab, 2012, 97(12): 4559-4570. 
																						 | 
										
																													
																							| 18 | 
																						 
											 Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality [J]. JAMA, 2013, 309(14): 1529-1530. 
																						 | 
										
																													
																							| 19 | 
																						 
											 Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer [J]. J Clin Oncol, 2015, 33(1): 42-50. 
																						 | 
										
																													
																							| 20 | 
																						 
											 Guo L, Ma Y, Yao Y, et al. Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma [J]. Sci Rep, 2019, 9(1): 75. 
																						 | 
										
																													
																							| 21 | 
																						 
											 Beiša A, Kvietkauskas M, Beiša V, et al. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage [J]. Langenbecks Arch Surg, 2017, 402(2): 227-234. 
																						 |